WHO ICTRP trial
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety…
EUCTR2008-005180-33-FR · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2008-005180-33-FR |
|---|---|
| Public title | A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with Solid Tumors |
| Scientific title | A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with Solid Tumors |
| Primary sponsor | Centocor B.V. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): Therapeutic use (Phase IV): |
| Countries | France;Belgium;Spain;United Kingdom |
| Conditions | Malignant solid tumors MedDRA version: 9.1 Level: LLT Classification code 10065147 Term: Malignant solid tumor |
| Interventions | Product Name: CNTO328 Product Code: CNTO328 Pharmaceutical Form: Powder for solution for infusion Current Sponsor code: CNTO328 Other descriptive name: chimeric murine-human monoclonal antibody against IL-6. Concentration unit: mg… |
| Registration date | Nov 14, 2008 |
| Target size | 90 |
| Secondary IDs | CNTO328STM2001 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: